Aclaris Therapeutics, Inc. — 2016 Q1 Form 10-Q Summary
Business context and reporting period
Clinical-stage specialty pharmaceutical company focused on dermatology. The filing covers the three months ended March 31, 2016, and was filed May 11, 2016. Lead candidate A-101 is a topical hydrogen peroxide solution being developed for seborrheic keratosis. During the quarter, the company initiated three Phase 3 A-101 trials and acquired Vixen Pharmaceuticals, adding JAK-inhibitor assets and related Columbia University rights.
Financial condition and results
| Metric | Q1 2016 | Q1 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $9.535 million | $1.737 million |
| General and administrative expense | $3.604 million | $0.892 million |
| Total operating expenses | $13.139 million | $2.629 million |
| Net loss | $13.039 million | $2.623 million |
| Net loss per share | $0.65 | $1.61 |
| Cash used in operating activities | $6.894 million | $2.802 million |
There was no meaningful operating margin because the company generated no revenue; the operating loss was $13.139 million. Other income was $100,000, primarily reflecting investment income. Comprehensive loss was $12.887 million.
At March 31, 2016, cash and cash equivalents were $13.131 million, marketable securities were $72.115 million, and total cash, cash equivalents and marketable securities were $85.246 million. Total assets were $87.270 million, total liabilities were $4.059 million, and stockholders’ equity was $83.211 million. The filing reports no debt or material ongoing financing commitments; liquidity obligations include the office sublease and contingent acquisition and licensing payments.
Investing activities provided $10.174 million, primarily from sales and maturities of marketable securities. Cash increased $3.280 million during the quarter. Stock-based compensation was $1.222 million, and $18.807 million of related expense remained unrecognized at March 31, 2016.
Material changes versus the prior comparable period
- Research and development expense increased $7.798 million, primarily due to $3.4 million of Vixen-related expenses, $1.4 million of additional JAK-inhibitor preclinical development, $2.0 million for A-101 Phase 3 initiation, and $0.3 million for the A-101 common-warts Phase 2 trial.
- General and administrative expense increased $2.712 million, driven by higher headcount and stock compensation, Vixen-related legal and patent costs, public-company professional fees, and a one-time $300,000 A-101 milestone payment.
- Net loss increased $10.416 million, while net loss per share improved from $1.61 to $0.65 because the weighted-average share count increased substantially following the 2015 IPO and preferred-stock conversion.
- Vixen was acquired on March 24, 2016 for $600,000 in cash, 159,420 common shares valued at $2.355 million, and additional annual, milestone and royalty obligations. The transaction was accounted for as an asset acquisition, and $2.784 million of non-cash acquisition-related charges were included in operating cash-flow reconciliation.
Guidance, outlook, risks and unusual items
Management expects significant operating losses and research and development spending to continue for the foreseeable future. If the A-101 Phase 3 trials are favorable, the company planned to submit an FDA New Drug Application in the fourth quarter of 2016. Management stated that existing cash, cash equivalents and marketable securities were expected to fund operations for more than 12 months from March 31, 2016, based on then-current assumptions, but additional capital would likely be needed for commercialization and further acquisitions or licensing.
Key risks include unsuccessful or delayed clinical trials, failure to obtain regulatory approval, patient-enrollment and manufacturing challenges, inability to raise capital on acceptable terms, competition, dependence on third-party vendors, and uncertain patent scope and enforceability. The company has substantial contingent obligations, including up to $80.0 million of pre-commercialization milestones and $10.0 million of additional development milestones under the Rigel agreement, as well as milestone and royalty obligations under the Vixen, Columbia University, JAKPharm, Key Organics and other agreements. No material legal proceedings were reported.
The company had no product revenue, had not achieved profitability, and stated that additional financing would be required to continue development and commercialization activities. It reported effective disclosure controls and no material changes in internal control over financial reporting.
Important facts for investors to verify
- Progress, enrollment, results and timing of the three A-101 Phase 3 trials and the expected NDA submission.
- Whether the stated cash runway remains adequate after incorporating ongoing clinical spending, commercialization preparation and Vixen-related obligations.
- Actual terms, probability and timing of milestone, royalty and annual payments under the Rigel, Vixen, Columbia University and other license agreements.
- Patent issuance, expiration, validity and freedom-to-operate risks for A-101 and the JAK-inhibitor programs.
- Future dilution from equity financing, stock options, restricted stock units or other capital-raising transactions.